Urinary loss of erythropoietin after intravenous versus subcutaneous epoetin-beta in preterm infants.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 18410782.
- Also identified by DOI 10.1016/j.jpeds.2008.01.026.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hematopoietic and non-hematopoietic effects of recombinant erythropoietin (Epo) given to preterm infants are controversially discussed. Because renal loss of Epo was significantly higher after intravenous versus subcutaneous Epoetin-beta administration, we suggest a reconsideration of whether subcutaneous recombinant Epo is more efficient and safer because of lower peaks of circulating Epo.
Medical subject headings
- Anemia, Neonatal
- Erythropoietin
- Infant, Premature, Diseases